Integrated Biologics Discovery Services from Target to IND

Target to IND and Beyond

The True Single-Source Advantage

We’ve expedited the path from target identification to IND for many of our 600+ global clients. By using our true single-source platforms and by integrating critical developability assessment into the discovery process, we can expedite your product into the clinic faster and more cost-effectively. End-to-End Integrated Discovery & Development Packages • Discovery Target to Lead • Preclinical Studies (DMPK, Tox, Biology)

What makes WuXi Biologics unique is our integrated, one-stop Discovery-to-IND biologics development platform and our full suite of discovery services which are available separately, as needed. Work with our highly experienced team of over 400+ scientists who have completed 500+ projects against 200+ targets covering different molecular modalities and disease indications. We have what you need to support your project, plus comprehensive single-source services for an all-inclusive solution to reduce your target to IND timeline by a remarkable 6-12 months.

• CMC Development • GMP Manufacturing • Global Regulatory Compliance

Core Competencies

Products enabled using our integrated discovery services: >20 Phase I & II Clinical >5 Phase III & Commercial

Based on your R&D goals, we tailor a program that will meet your discovery needs. All of our discovery technologies and platforms take advantage of our core competencies: • World-class research expertise • State-of-the-art facilities • Well-established project management systems • Efficient workflows • Demonstrated success in generating antibodies against a multitude of targets and identification of preclinical candidates (PCCs) in all disease areas

BECAUSE DEVELOPMENT BEGINS WITH

Contact us to learn more: info@wuxibiologics.com

By linking discovery with development, we can reduce your timeline from Concept to IND by 6-12 months.

About WuXi Biologics

WuXi Biologics is a leading contract research, development and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in China, the United States, Ireland, Germany, and Singapore, we enable our partners to effectively and efficiently bring biologics and vaccines to patients worldwide through our comprehensive and high-quality drug development model.

wuxibiologics.com | info@wuxibiologics.com The world’s leading global single-source platform from concept to commercialization.

11-20-2023

Powered by